Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: Role of myosin light-chain kinase protein expression

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 3 51-3, 2005, Pages

  Ma, Thomas Y ^a   Boivin, Michel A ^b   Ye, Dongmei ^b   Pedram, Ali ^b   Said, Hamid M ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Intestinal barrier; Intestinal permeability; Tight junctions

Indexed keywords

CYCLOHEXIMIDE; MESSENGER RNA; MYOSIN LIGHT CHAIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MODEL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TIGHT JUNCTION;

ANTIMETABOLITES; BLOTTING, WESTERN; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DACTINOMYCIN; DNA PRIMERS; HUMANS; IMMUNOPRECIPITATION; METHIONINE; MYOSIN-LIGHT-CHAIN KINASE; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM AZIDE; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13844308129     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00412.2004     Document Type: Article

References (47)

1. Adelstein R. Regulation and kinetics of the actin-myosin-ATP interaction. Annu Rev Biochem 49: 921-956, 1980.
2. Allen U and Jones V. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Dig Dis Sci 32: 100-108, 1986.
3. Braegger CP, Nicholls S, Murch SH, Stephens S, and MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89-91, 1992.
4. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, and Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271-1277, 1999.
5. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, and Gleim G. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95: 1859-1861, 2000.
6. Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emilie D, Colombel JF, Garcia-Villar R, Fioramonti J, and Bueno L. Stress-induced disruption of colonic epithelial barrier: role of interferon-γ and myosin light chain kinase in mice. Gastroenterology 125: 795-804, 2003.
7. Gitter AH, Bendfeldt K, Schmitz H, Schulzke JD, Bentzel CJ, and Fromm M. Epithelial barrier defects in HT-29/B6 colonie cell monolayers induced by tumor necrosis factor-α. Ann NY Acad Sci 915: 193-203, 2000.
8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, and Colombel JF. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359: 1541-1549, 2002.
9. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, and Madara JL. Clostridium difficile toxin B disrupts the barrier function of T84 mono-layers. Gastroenterology 102: 416-423, 1992.
10. Hidalgo IJ, Raub TJ, and Borchardt RT. Characterization of human colon carcinoma cell line (Caco-2) as a model system of intestinal epithelial permeability. Gastroenterology 96: 736-749, 1989.
11. Hollander D. Crohn's disease-a permeability disorder of the tight junction? Gut 26: 1621-1624, 1988.
12. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty TJ, and Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 105: 883-885, 1986.
13. Itoh T, Ikebe M, Kargacin G, Hartshorne D, Kemp B, and Fay F. Effects of modulators of myosin light-chain kinase activity in single smooth muscle cells. Nature 338: 164-167, 1989.
14. Kamm K and Stull J. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu Rev Pharmacol Toxicol 25: 593-620, 1985.
15. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza D, Krugliak P, and Rotter JI. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97: 927-931, 1989.
16. Kaufmann HJ and Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107: 513-516, 1987.
17. Kirsner JB and Shorter RG. Recent developments in nonspecific inflammatory bowel disease. N Engl J Med 306: 837-848, 1982.
18. Ma TY. Intestinal epithelial barrier dysfunction in Crohn's disease. Proc Soc Exp Biol Med 214: 318-327, 1997.
19. Ma TY, Hoa NT, Tran DD, Bui V, Pedram A, Mills S, and Merryfield M. Cytochalasin B modulation of Caco-2 tight junction barrier: role of myosin light chain kinase. Am J Physiol Gastrointest Liver Physiol 279: G875-G885, 2000.
20. Ma TY, Hollander D, Nguyen H, Bhalla D, and Krugliak P. IEC-18 a non-transformed small intestinal cell line for studying epithelial permeability. J Lab Clin Med 120: 329-341, 1992.
21. Ma TY, Hollander D, Riga R, and Bhalla D. Autoradiographic determination of permeation pathway of permeability probes across intestinal and tracheal epithelia. J Lab Clin Med 122: 590-600, 1993.
22. Ma TY, Hollander D, Tran LT, Nguyen D, Hoa N, and Bhalla D. Cytoskeletal regulation of Caco-2 intestinal monolayer paracellular permeability. J Cell Physiol 164: 533-545, 1995.
23. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, and Said HM. TNF-α-induced increase in intestinal epithelial tight junction permeability requires NT-κB activation. Am J Physiol Gastrointest Liver Physiol 286: G367-G376, 2004.
24. Ma TY, Nguyen D, Bui V, Hoa N, and Nguyen H. Ethanol modulation of Caco-2 intestinal monolayer paracellular permeability. Am J Physiol Gastrointest Liver Physiol 39: G965-G974, 1999.
25. Ma TY, Tran D, Hoa N, Nguyen D, Merryfield M, and Tarnawski A. Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. Microsc Res Tech 51: 156-168, 2000.
26. Marano CW, Lewis SA, Garulacan LA, Soler AP, and Mullin JM. Tumor necrosis factor-α increases sodium and chloride conductance across the tight junction of Caco-2 BBE, a human intestinal epithelial cell line. J Membr Biol 161: 263-274, 1998.
27. May GR, Sutherland LR, and Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 104: 1627-1632, 1993.
28. Murch SH, Braegger CP, Walker-Smith JA, and MacDonald TT. Location of tumour necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709, 1993.
29. O'Morain C, Segal AW, and Levi AJ. Elemental diets in treatment of acute Crohn's disease. Br Med J 281: 1173-1175, 1980.
30. 1 renal epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 270: F869-F879, 1996.
31. Petrache I, Verin AD, Crow MT, Birukova A, Liu F, Garcia JGN. Differential effect of MLC kinase in TNF-α induced endothelial cell apoptosis and barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 280: L1168-L1178, 2001.
32. Pinto M, Robine-Leon S, Tappay M, Kedinger M, Triadou N, Dussayi M, Lacvri B, Simon-Assway P, Haffer K, Fough J, and Zwiebaum A. Enterocyte-like differentiation and polarization if the human colon carcinoma cell line Caco-2 in culture. Biocell 47: 323-330, 1983.
33. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, and Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96: 722-729, 2001.
34. Rodriguez P, Heyman M, Candalh C, Blaton MA, and Bouchaud C. Tumour necrosis factor-α induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers. Cytokine 7: 441-448, 1995.
35. Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 3: 95-113, 1997.
36. Schmilz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J, Bode H, Epple HJ, Riecken EO, and Schulzke JD. Tumor necrosis factor-α (TNF-α) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 112: 137-146, 1999.
37. Svenaert P, Bulteel V, Lemmen L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, and Rutgeerts P. Anti-TNF treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol Suenaert P, Bulteel V, Lemmens L, 197: 2000-2004, 2002.
38. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, and Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94: 6444-6449, 1997.
39. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. N Engl J Med 337: 1029-1035, 1997.
40. Turner J, Rill BK, Carlson SL, Carnes D, Kerner R, Marny RJ, Madara JL. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol Cell Physiol 273: C1378-C1385, 1997.
41. Van Deventer SJ. Tumor necrosis factor and Crohn's disease. Gut 40: 443-448, 1997.
42. Wick DA, Seetharam B, and Dahms NM. Biosynthesis and secretion of the mannose 6-phosphate receptor and its ligands in polarized Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 277: G506-G514, 1999.
43. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, and Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341: 1437-1439, 1993.
44. Yu J, Farjo R, MacNee SP, Baehr W, Stambolian DE, and Swaroop A. Annotation and analysis of 10,000 expressed sequence tags from developing mouse eye and adult retina. Genome Biol 4: R65.1-R65.17, 2003.
45. Yuhan R, Koutsouri A, Savkovic SD, and Hecht G. Enteropathogenic Eschrichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 113: 1873-1882, 1997.
46. Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, and Gasbarrini G. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther 11: 735-740, 1997.
47. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, and Turner JR. A memhrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123: 163-172, 2002.